Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,319 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,657 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03564340 | Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers | recruiting | Phase 1 / Phase 2 | 890 | Regeneron PharmaceuticalsINDUSTRY | 10 | Sep 25, 2026 | clinicaltrials |
| NCT03896568 | MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma | recruiting | Phase 1 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 |
| NCT04094610 | A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations | recruiting | Phase 1 / Phase 2 | 75 | Turning Point Therapeutics, Inc.INDUSTRY | 11 | Sep 25, 2026 | clinicaltrials |
| NCT04811560 | A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)(cAMeLot-1) | recruiting | Phase 1 / Phase 2 | 420 | Janssen Research & Development, LLCINDUSTRY | 13 | Sep 25, 2026 | clinicaltrials |
| NCT04925479 | Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 34 | Novartis PharmaceuticalsINDUSTRY | 14 | Sep 25, 2026 | clinicaltrials |
| NCT05099003 | A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) | recruiting | Phase 1 / Phase 2 | 132 | National Cancer Institute (NCI)NIH | 4 | Sep 25, 2026 | clinicaltrials |
| NCT06005493 | Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 392 | AstraZenecaINDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT06218914 | Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors | recruiting | Phase 1 | 108 | AstraZenecaINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06224855 | A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies | recruiting | Phase 1 | 280 | Hangzhou DAC Biotechnology Co., Ltd.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06385080 | A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer(OrigAMI-4) | recruiting | Phase 1 / Phase 2 | 287 | Janssen Research & Development, LLCINDUSTRY | 11 | Sep 25, 2026 | clinicaltrials |
| NCT06401603 | A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid Leukemia | recruiting | Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06428409 | A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) | recruiting | Phase 1 / Phase 2 | 220 | Merck Sharp & Dohme LLCINDUSTRY | 13 | Sep 25, 2026 | clinicaltrials |
| NCT06441331 | Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors(KinLET) | recruiting | Phase 1 | 20 | ITM Solucin GmbHINDUSTRY | 3 | Sep 25, 2026 | clinicaltrials |
| NCT06548230 | A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) | recruiting | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06768489 | A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma | recruiting | Phase 1 | 276 | Janssen Research & Development, LLCINDUSTRY | 5 | Sep 25, 2026 | clinicaltrials |
| NCT06801236 | Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 | 88 | Acerand Therapeutics (Hong Kong) LimitedINDUSTRY | 2 | Sep 25, 2026 | clinicaltrials |
| NCT06820268 | A Study of XS-04 in Patients With Relapsed or Refractory Hematologic Malignancies | recruiting | Phase 1 | 168 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07037758 | A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)(DeLLphi-311) | recruiting | Phase 1 | 380 | AmgenINDUSTRY | 3 | Sep 25, 2026 | clinicaltrials |
| NCT07060014 | NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers | recruiting | Phase 1 | 22 | The Methodist Hospital Research InstituteOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07219212 | A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma(LUMIRAY) | recruiting | Phase 1 | 45 | Johnson & Johnson Enterprise Innovation Inc.INDUSTRY | 3 | Sep 25, 2026 | clinicaltrials |
| NCT07227025 | A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer(KaRAnaSa) | recruiting | Phase 1 / Phase 2 | 60 | Janssen Research & Development, LLCINDUSTRY | 5 | Sep 25, 2026 | clinicaltrials |
| NCT07227298 | Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers | recruiting | Phase 1 / Phase 2 | 162 | PfizerINDUSTRY | 9 | Sep 25, 2026 | clinicaltrials |
| NCT07336472 | A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 360 | Fortvita Biologics (USA)Inc.INDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07476326 | Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma | recruiting | Phase 1 | 120 | Biocon Biologics UK PLCINDUSTRY | 10 | Sep 25, 2026 | clinicaltrials |
| NCT07519772 | A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)(WaveSpan-008) | recruiting | Phase 1 / Phase 2 | 280 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Sep 25, 2026 | clinicaltrials |
| NCT07572006 | A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies | recruiting | Phase 1 | 360 | Janssen Research & Development, LLCINDUSTRY | 7 | Sep 25, 2026 | clinicaltrials |
| NCT07579221 | Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07670312 | Evaluation of XYA02 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 190 | XYone Therapeutics, IncINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07748988 | Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Cell Carcinoma | recruiting | Phase 1 | 12 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07838714 | Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia | recruiting | Phase 1 | 18 | Ruijin HospitalOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT03661307 | Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome | recruiting | Phase 1 / Phase 2 | 73 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT03874052 | Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 51 | Jennifer SaultzOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05412225 | A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer | recruiting | Phase 1 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05949125 | Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (1b Dose Expansion)(RevSTAR-123) | recruiting | Phase 1 | 37 | AvenCell Europe GmbHINDUSTRY | 2 | Sep 24, 2026 | clinicaltrials |
| NCT06047379 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | recruiting | Phase 1 / Phase 2 | 134 | Neonc Technologies, Inc.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06871410 | Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | recruiting | Phase 1 | 26 | Roswell Park Cancer InstituteOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07408856 | CAN1012 in Pre-Malignant DCIS and LCIS | recruiting | Phase 1 | 24 | Providence Health & ServicesOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07559929 | A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer. | recruiting | Phase 1 / Phase 2 | 200 | Hangzhou DAC Biotechnology Co., Ltd.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07719361 | A Study in Patients With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 | 60 | Flare Therapeutics Inc.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT03816345 | Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO | recruiting | Phase 1 | 300 | National Cancer Institute (NCI)NIH | 2 | Sep 23, 2026 | clinicaltrials |
| NCT04222413 | Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors | recruiting | Phase 1 | 116 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT04301076 | Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05320198 | Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia | recruiting | Phase 1 / Phase 2 | 150 | Disc Medicine, IncINDUSTRY | 2 | Sep 23, 2026 | clinicaltrials |
| NCT05360160 | A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE) | recruiting | Phase 1 / Phase 2 | 43 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06102902 | Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06302621 | Pemigatinib + Afatinib in Advanced Refractory Solid Tumors | recruiting | Phase 1 | 32 | Massachusetts General HospitalOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06308588 | Phase I/II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | recruiting | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06389591 | RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM) | recruiting | Phase 1 | 24 | University of FloridaOTHER | 1 | Sep 23, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 25, 2026source: clinicaltrials